Skip to main content

Table 4 Effects of treatment with Tridax procumbens extract on Fasting blood glucose (FBG) in normal and alloxan diabetic rats.

From: Evaluation of hypoglycemic and anti-hyperglycemic potential of Tridax procumbens (Linn.)

Group

(n = 6)

Dose

(mg/kg)

Alloxaα) dosing

Days after dosing

   

0 dβ)

7 d

15 d

21 d

30 dγ)

Normal Control

-

81.21 ± 2.1a

79.00 ± 1.8a

86.12 ± 2.0a

77.45 ± 2.6a

83.20 ± 3.1a

80.16 ± 3.6a

Normal+ Extract

250

78.54 ± 2.4a

77.20 ± 2.6a

79.20 ± 3.5a

76.56 ± 4.8a

75.00 ± 3.5a

76.60 ± 3.0a

Normal+ Extract

500

83.20 ± 1.8a

80.63 ± 3.0a

84.25 ± 2.9a

79.36 ± 6.2a

74.25 ± 5.2a

73.60 ± 5.8b

Diabetic Control

-

80.16 ± 1.6a

452.35 ± 4.6b

470.20 ± 6.2b

459.48 ± 11.2b

495.00 ± 9.2c

512.40 ± 9.6c

Diabetic+ Extract

250

82.00 ± 2.8a

454.16 ± 5.4b

299.30 ± 10.2c

(34.09)

215.00 ± 9.6d

(28.16)

186.82 ± 14.7e

(13.10)

171.24 ± 12.5f

(8.33)

Diabetic+ Extract

500

84.40 ± 2.4a

468.20 ± 4.6b

289.50 ± 8.6c

(38.16)

204.20 ± 12.3d

(29.46)

179.42 ± 11.6e

(12.13)

166.00 ± 10.2f

(7.47)

Diabetic+ Glibenc-lamide

10

79.78 ± 2.1a

483.83 ± 6.8b

394.14 ± 9.2c

(18.53)

293.20 ± 14.3d

(25.61)

258.40 ± 12.9e

(11.86)

242.00 ± 11.4e

(6.34)

  1. Values represent mean ± SEM (n = 6).
  2. *Values for a given group in a row followed by same letter as superscript are not significantly different according to Tukey's multiple comparison procedure (at P < 0.05).
  3. α) At alloxan dosing; β) at initial dosing after fasting (15 d after alloxan dosing); γ) at sacrifice after fasting
  4. Values given in parenthesis are percent (%) glucose reduction, compared to previous observation of their respective group (in rows)